Difference between revisions of "Part:BBa K4593002:Design"

(→‎Design Notes)
(→‎Source)
Line 11: Line 11:
 
===Source===
 
===Source===
  
−
Hybrid endolysin from domains of 12 natural staphylococcal endolysins.
+
Hybrid endolysin with CBD of LysPALS1 and EAD of LysSA12.
  
 
===References===
 
===References===
 
Lee, Chanyoung, et al. “Development of Advanced Chimeric Endolysin to Control Multidrug-Resistant Staphylococcus Aureus through Domain Shuffling.” ACS Infectious Diseases, vol. 7, no. 8, 28 May 2021, pp. 2081–2092.
 
Lee, Chanyoung, et al. “Development of Advanced Chimeric Endolysin to Control Multidrug-Resistant Staphylococcus Aureus through Domain Shuffling.” ACS Infectious Diseases, vol. 7, no. 8, 28 May 2021, pp. 2081–2092.
 
https://doi.org/10.1021/acsinfecdis.0c00812.
 
https://doi.org/10.1021/acsinfecdis.0c00812.

Revision as of 15:14, 3 October 2023


ClyC


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 681
    Illegal AgeI site found at 550
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

N/A

Source

Hybrid endolysin with CBD of LysPALS1 and EAD of LysSA12.

References

Lee, Chanyoung, et al. “Development of Advanced Chimeric Endolysin to Control Multidrug-Resistant Staphylococcus Aureus through Domain Shuffling.” ACS Infectious Diseases, vol. 7, no. 8, 28 May 2021, pp. 2081–2092. https://doi.org/10.1021/acsinfecdis.0c00812.